CGRP Migraine Medication Denied by Insurance? How to Appeal

CGRP (calcitonin gene-related peptide) medications represent the first migraine-specific preventive and acute treatments developed in decades — and they are among the most frequently denied specialty medications due to their cost ($500–$900 per month). If your insurer denied Aimovig, Ajovy, Emgality, Vyepti, Nurtec, Ubrelvy, or Qulipta, you have strong grounds for appeal. The American Headache Society (AHS) 2021 Consensus Statement recommends CGRP-targeted therapy for patients who have failed two prior preventive medication classes — a threshold far lower than the four or more failures many insurers require. This guide shows you how to build a compelling, evidence-based appeal.

Why Insurers Deny CGRP Migraine Drugs

Insurers deny CGRP medications through several predictable gatekeeping mechanisms:

• Step therapy failures not documented — Plans universally require trial and failure of multiple preventive medications (beta-blockers, tricyclic antidepressants, anticonvulsants, calcium channel blockers) before approving CGRP inhibitors
• Migraine frequency threshold not met — Most Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria require episodic migraine of at least 4 migraine days per month, or chronic migraine defined as at least 15 headache days per month with at least 8 migraine days (International Headache Society definition)
• Inadequate headache diary documentation — Insurers require contemporaneous diary documentation of migraine frequency, not just a physician statement; a headache diary from the previous 1–3 months is essential
• Triptan failure not established for gepants — Plans prefer triptans for acute migraine and require evidence of triptan failure before approving Nurtec or Ubrelvy
• "Not medically necessary" for preventive therapy — Insurers argue symptoms can be managed with oral preventives despite documented failure or contraindication
• Step therapy violation of state law — Many states including New York, Texas, Illinois, and Virginia require insurers to grant step therapy exceptions when required medications are contraindicated, previously failed, or when a patient is stable on the current medication

How to Appeal a CGRP Migraine Drug Denial

Step 1: Document Migraine Diagnosis and Frequency Precisely

Your headache specialist or neurologist must provide a formal migraine diagnosis per International Headache Society Classification: 1.1 Migraine Without Aura (ICD-10: G43.0), 1.2 Migraine With Aura (G43.1), or 1.3 Chronic Migraine (G43.3). Provide a 3-month headache diary documenting migraine days, severity, associated symptoms, and functional impairment. Include MIDAS (Migraine Disability Assessment) or HIT-6 (Headache Impact Test) scores — a HIT-6 score of 60 or above indicates substantial impact and strongly supports medical necessity.

Step 2: Document Prior Preventive Medication Failures in Detail

List every preventive tried with drug name, therapeutic class, dose, duration of adequate trial (at least 6–8 weeks at therapeutic dose), and reason for failure — either inadequate efficacy (still having 4 or more migraine days per month) or intolerance or adverse effects. Required preventive classes typically include beta-blockers (propranolol, timolol, metoprolol), tricyclic antidepressants (amitriptyline, nortriptyline), anticonvulsants (topiramate, valproate or divalproex), calcium channel blockers (verapamil), and SNRIs (venlafaxine). If any are contraindicated — asthma for beta-blockers, pregnancy for valproate, cognitive side effects for topiramate — document the contraindication explicitly.

Step 3: Document Triptan Failure for Gepant Appeals

For Nurtec or Ubrelvy appeals specifically, demonstrate which triptans were tried, why each provided inadequate response or caused adverse effects, and any medical contraindications to triptans such as cardiovascular disease, uncontrolled hypertension, or hemiplegic migraine. Document medication overuse headache (MOH) concerns where applicable, as gepants do not carry MOH risk the way triptans do.

Step 4: Cite AHS and AAN Clinical Guidelines Directly

The AHS 2021 Consensus Statement explicitly recommends CGRP inhibitors as high-value therapy for episodic and chronic migraine prevention in patients who have failed two prior preventive medication classes. Note in your appeal that your insurer's criteria requiring four or more failures exceeds this published clinical standard. The American Academy of Neurology (AAN) Practice Guidelines affirm CGRP monoclonal antibodies as effective and well-tolerated preventive options for migraine. Under ERISA (for employer plans) and ACA provisions, medical necessity must be assessed against recognized clinical standards, not arbitrary internal criteria.

Step 5: Document Quality of Life Impact and Disability

Include work absences and lost productivity caused by migraine days, emergency room visits or urgent care for refractory migraine (typical ER visit cost: $2,000 or more), risk of medication overuse headache with excessive triptan or NSAID use, HIT-6 score of 60 or above indicating substantial daily life impact, and any failed onabotulinumtoxinA (Botox) trials for chronic migraine patients.

Step 6: File the Internal Appeal and Request External Independent Review: Complete Guide" class="auto-link">External Review

Submit your complete appeal package to your insurer's appeals department within the deadline (typically 180 days for commercial plans). For urgent cases, request an expedited appeal. If the internal appeal is denied, immediately request external review by an IROs) Explained" class="auto-link">Independent Review Organization (IRO) — this is free under the ACA, binding on the insurer, and external reviews for specialty drug denials overturn insurer decisions at high rates when clinical guidelines clearly support the medication.

What to Include in Your CGRP Appeal

• Written denial letter with specific reason code and prior authorization criteria cited
• List of all prior preventive medications tried with dates, doses, duration, and reason for failure (organized by drug class)
• 3-month headache diary documenting migraine days, severity, and functional impairment
• Neurologist or headache specialist letter confirming diagnosis and CGRP recommendation with AHS guideline citations
• MIDAS or HIT-6 scores, documentation of any triptan failures for gepant appeals, and records of ER visits for refractory migraine

Fight Back With ClaimBack

CGRP migraine appeals require documenting headache frequency, prior preventive failures by therapeutic class, and clinical guideline citations that directly counter your insurer's prior authorization criteria. ClaimBack generates a professional CGRP appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal